Hanmi pacts with Tabuk Pharmaceuticals to expand into MENA

user icon
NOHA.GAD
calender icon
Oct 10, 2024
article image

Riyadh - Sharikat Mubasher: South Korea’s Hanmi Pharmaceutical entered into an exclusive licensing agreement with the Saudi leading pharmaceuticals company Tabuk Pharmaceuticals to export its flagship products to the Middle East and North Africa (MENA) region.

In a statement, Hanmi revealed that it will export its innovative new drugs that have already received validation in key markets such as the United States and South Korea.

Through this partnership, the South Korean company aims to gradually expand its product offerings and strengthen its presence in the region over time.

The signing ceremony was attended by Ismail Shehada, CEO of Tabuk Pharmaceutical, Wisam Al Khatib, CBO of Tabuk Pharmaceutical, Ju Hyun Lim, Vice Chairman of Hanmi Pharmaceutical, and representatives from Hanmi Pharmaceuticals Global Headquarters.

The partnership will enable Tabuk Pharmaceutical to obtain local approvals and commence the full-scale commercialization of several innovative and specialized pharmaceutical products developed by Hanmi.

Both companies aspire to introduce cutting-edge treatments across the region and improve healthcare outcomes, leveraging their cutting-edge research and Development capabilities.

CEO Shehada stated that the partnership will enable the company to introduce innovative therapies to the MENA region.

“Our combined expertise will ensure these breakthrough treatments reach healthcare providers and patients, bringing meaningful value to the healthcare system,” Shehada added.

On his part, Hanmi’s Vice Chairman, commented: " This partnership reflects our mutual dedication to addressing significant healthcare challenges and improving patient outcomes. We can create synergy by combining Hanmi's research expertise with Tabuk's strong regional presence. We will do our best to bring meaningful changes to patients' lives in the MENA region."

It is worth mentioning that the initial rollout will focus on urology treatments and anticancer biopharmaceuticals, marking the first wave of products to enter the market. 


Share

Related News

Monsha’at refunds over SAR 400 mn to eligible SMEs under Estrdad initiative
News
Calendar Icon
November 18, 2026
Monsha’at refunds over SAR 400 mn to eligible SMEs under Estrdad initiative
Read More
Shein seeks to expand partnerships with local brands in Saudi Arabia
News
Calendar Icon
November 18, 2026
Shein seeks to expand partnerships with local brands in Saudi Arabia
Read More
Signit partners with VANDI to expand digital solutions in Saudi Arabia
News
Calendar Icon
November 18, 2026
Signit partners with VANDI to expand digital solutions in Saudi Arabia
Read More
Qualcomm eyes AI ecosystem expansion in Saudi Arabia
News
Calendar Icon
November 18, 2026
Qualcomm eyes AI ecosystem expansion in Saudi Arabia
Read More
Brand Finance names PIF as world’s most valuable SWF brand
News
Calendar Icon
November 18, 2026
Brand Finance names PIF as world’s most valuable SWF brand
Read More
Saudi Arabia's Logistics Commercial Registrations Rise 35% in 2026
News
Calendar Icon
November 17, 2026
Saudi Arabia's Logistics Commercial Registrations Rise 35% in 2026
Read More
iMENA completes SAR 800 mn capital increase to fuel expansion
News
Calendar Icon
November 17, 2026
iMENA completes SAR 800 mn capital increase to fuel expansion
Read More
du unveils National HyperAI to scale AI adoption across UAE
News
Calendar Icon
November 16, 2026
du unveils National HyperAI to scale AI adoption across UAE
Read More
Monsha’at signed several agreements to strengthen Saudi entrepreneurship ecosystem
News
Calendar Icon
November 16, 2026
Monsha’at signed several agreements to strengthen Saudi entrepreneurship ecosystem
Read More
UAE-based fintech firm Mal opens new office in Egypt
News
Calendar Icon
November 15, 2026
UAE-based fintech firm Mal opens new office in Egypt
Read More